These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27908534)

  • 41. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
    Moghadam-Kia S; Oddis CV; Aggarwal R
    Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous immunoglobulins for refractory status epilepticus, part I: A scoping systematic review of the adult literature.
    Zeiler FA; Matuszczak M; Teitelbaum J; Kazina CJ; Gillman LM
    Seizure; 2017 Feb; 45():172-180. PubMed ID: 28068584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis.
    Goswami RP; Haldar SN; Chatterjee M; Vij P; van der Kooi AJ; Lim J; Raaphorst J; Bhadu D; Gelardi C; Danieli MG; Kumar U
    Autoimmun Rev; 2022 Feb; 21(2):102997. PubMed ID: 34800685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies.
    Dalakas MC
    Clin Exp Immunol; 1996 May; 104 Suppl 1():55-60. PubMed ID: 8625545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies.
    de Souza JM; Hoff LS; Shinjo SK
    Rheumatol Int; 2019 Jul; 39(7):1201-1212. PubMed ID: 30778655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
    Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
    Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.
    Bae S; Charles-Schoeman C
    Clin Rheumatol; 2018 Aug; 37(8):2113-2123. PubMed ID: 29971584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous immunoglobulin therapy for refractory myositis.
    Moriguchi M; Suzuki T; Tateishi M; Hara M; Kashiwazaki S
    Intern Med; 1996 Aug; 35(8):663-7. PubMed ID: 8894745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
    Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
    Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and new targets for treating myositis.
    Moghadam-Kia S; Oddis CV
    Curr Opin Pharmacol; 2022 Aug; 65():102257. PubMed ID: 35724455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulin: striving for appropriate use.
    Kumar A; Teuber SS; Gershwin ME
    Int Arch Allergy Immunol; 2006; 140(3):185-98. PubMed ID: 16682800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
    Cherin P
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
    Raju R; Dalakas MC
    Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis.
    Hoff LS; de Souza FHC; Miossi R; Shinjo SK
    Rheumatology (Oxford); 2022 Apr; 61(4):1579-1588. PubMed ID: 34302454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies.
    Anang DC; Walter HAW; Lim J; Niewold I; van der Weele L; Aronica E; Eftimov F; Raaphorst J; van Schaik BDC; van Kampen AHC; van der Kooi AJ; de Vries N
    Rheumatology (Oxford); 2023 Jul; 62(7):2585-2593. PubMed ID: 36321862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Current therapy for polymyositis and dermatomyositis].
    Chérin P
    Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy of polymyositis and dermatomyositis.
    Marie I; Mouthon L
    Autoimmun Rev; 2011 Nov; 11(1):6-13. PubMed ID: 21740984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biologics for idiopathic inflammatory myopathies.
    Moghadam-Kia S; Aggarwal R; Oddis CV
    Curr Opin Rheumatol; 2017 Nov; 29(6):645-651. PubMed ID: 28817464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis.
    Saito E; Koike T; Hashimoto H; Miyasaka N; Ikeda Y; Hara M; Yamada H; Yoshida T; Harigai M; Ichikawa Y
    Mod Rheumatol; 2008; 18(1):34-44. PubMed ID: 18217197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Intravenous immunoglobulin treatment in idiopathic inflammatory myopathy].
    Bodoki L; Vincze M; Griger Z; Dankó K
    Orv Hetil; 2013 May; 154(19):723-8. PubMed ID: 23649636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.